Skip to main
OBIO
OBIO logo

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. demonstrates a positive outlook supported by strategic operational advancements, highlighted by a significant increase in eligible patient pools due to protocol updates, potentially enhancing product adoption and market reach. The company’s research and development investments, which rose by 21% year-over-year to $14.0 million, reflect a commitment to innovation and the advancement of its flagship therapies, bolstering its long-term growth trajectory. Additionally, the publication of promising clinical data further strengthens the credibility of its offerings, positioning the company favorably within the competitive landscape of biomedical solutions.

Bears say

Orchestra BioMed Holdings Inc. has consistently incurred operating losses since its inception, raising concerns about its ability to achieve sustainable profitability. The lengthy and potentially costly nature of clinical trials presents a risk, as these trials may not successfully demonstrate the safety and efficacy of its flagship product candidates. Furthermore, the company's key intellectual property may not adequately protect its innovations, adding to the uncertainty surrounding its future financial performance.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.